Thermo Fisher Scientific, Inc. (TMO)
What changed in recent filings
- Revenue +10% YoYQuarter ended Jun 27, 2026
- Institutions — 1 new · 5 added · 5 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Thermo Fisher Scientific, Inc. recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Jul 23, 2026Revenue +10.5% YoY · EPS $4.68Released before the open: Jul 22 close → Jul 23 close, the stock moved +8.7% · over the same window, market -1.2% · sector +0.5%
- 26Q1Released Apr 23, 2026Revenue +6.2% YoY · EPS $4.43Released before the open: Apr 22 close → Apr 23 close, the stock moved -9.2% · over the same window, market -0.4% · sector -0.2%
- 25Q4Released Jan 29, 2026Revenue +7.2% YoY · EPS $5.21Released before the open: Jan 28 close → Jan 29 close, the stock moved -2.6% · over the same window, market -0.2% · sector -0.1%
- 25Q3Released Oct 22, 2025Revenue +4.9% YoY · EPS $4.27Released before the open: Oct 21 close → Oct 22 close, the stock moved +1.7% · over the same window, market -0.5% · sector -0.1%
Institutions holding Thermo Fisher Scientific, Inc.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 10 → 2026 Q2: 13 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Thermo Fisher Scientific, Inc.
Institutions we track that reported holding this stock in their most recent 13F.
- Temasek Holdings (Singapore)1.57% of portfolio · held as of 2019 Q1 or earlier
- Baillie Gifford & Co0.29% of portfolio · held as of 2019 Q1 or earlier
- National Pension Service (Korea)0.27% of portfolio · held as of 2019 Q1 or earlier
- Dodge & Cox0.80% of portfolio · held as of 2019 Q1 or earlier
- PRIMECAP Management0.59% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)0.15% of portfolio · held as of 2019 Q1 or earlier
- Capital World Investors0.37% of portfolio · held as of 2020 Q3 or earlier
- Point72 Asset Management0.15% of portfolio · since 2024 Q4
- Glenview Capital Management5.73% of portfolio · since 2025 Q2
- Tudor Investment Corp0.05% of portfolio · since 2025 Q4
- Viking Global Investors2.77% of portfolio · since 2025 Q4
- Bridgewater Associates0.03% of portfolio · since 2025 Q4
- Duquesne Family OfficeNew this quarter0.18% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
Thermo Fisher Scientific Inc. is a global life sciences company that provides analytical instruments, laboratory products, specialty diagnostics, and biopharma services. Its portfolio supports scientific research, clinical testing, drug discovery, and pharmaceutical manufacturing through a broad range of instruments, reagents, consumables, software, and services. The company serves customers across pharmaceutical and biotechnology firms, hospitals, clinical diagnostic laboratories, universities, research institutions, and government agencies. Thermo Fisher Scientific Inc. operates through several business segments that address research, analysis, diagnostics, and laboratory workflow needs, making it an important supplier to healthcare, industrial, and scientific markets worldwide. Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. is recognized for its role in enabling laboratory productivity and supporting the development, testing, and production of modern therapies and diagnostics.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Thermo Fisher Scientific, Inc. is classified under the Biotech & Health sector. See peers below.
Thermo Fisher Scientific, Inc. key financials
Based on SEC filings · as of Jun 27, 2026
Tap a metric name to see its meaning in the glossary.
Thermo Fisher Scientific, Inc. vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
TMO revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-27 revenue was $12.0B, +10.5% YoY.
The largest segment is Laboratory Products and Biopharma Services, 55.5% of revenue — a concentrated structure.
Recent revenue growth was led mainly by the Laboratory Products and Biopharma Services segment (about 61% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
ETFs holding Thermo Fisher Scientific, Inc.
Per SEC N-PORT · 2026-06-30 · by weight · factual
TMO on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
TMO FAQ
What is Thermo Fisher Scientific, Inc. (TMO)?
Thermo Fisher Scientific Inc. is a global life sciences company that provides analytical instruments, laboratory products, specialty diagnostics, and biopharma services. Its portfolio supports scientific research, clinical testing, drug discovery, and pharmaceutical manufacturing through a broad range of instruments, reagents, consumables, software, and services. The company serves customers across pharmaceutical and biotechnology firms, hospitals, clinical diagnostic laboratories, universities, research institutions, and government agencies. Thermo Fisher Scientific Inc. operates through several business segments that address research, analysis, diagnostics, and laboratory workflow needs, making it an important supplier to healthcare, industrial, and scientific markets worldwide. Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. is recognized for its role in enabling laboratory productivity and supporting the development, testing, and production of modern therapies and diagnostics.
What sector is Thermo Fisher Scientific, Inc. in?
Thermo Fisher Scientific, Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Thermo Fisher Scientific, Inc.'s key financials?
As of Jun 27, 2026 in SEC filings: Revenue growth (YoY) 7.2%, Operating margin 17.4%, Net margin 15.0%, ROE 12.6%, Debt-to-equity 0.80x. Definitions and interpretation are available on Stocklore.
What are Thermo Fisher Scientific, Inc.'s main revenue segments?
The largest segment is Laboratory Products and Biopharma Services, about 55.5% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Thermo Fisher Scientific, Inc. (TMO) stock?
On Stocklore you can see TMO's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.